tissue, disease associated with dysregulation of the HGF/c-met signaling axis, the proliferative and/or the cancer is characterized by c-met expression or activity. In some embodiments, c-met expression is c-met over-expression.

[0037] In addition, provided herein are articles of manufacture comprising a container with a composition, lot, or pharmaceutical formulation described above contained therein. Further provided herein are methods of making the article of manufacture.

[0038] In one aspect, there is provided a composition comprising an anti-c-met antibody, wherein host cell protein (HCP) is between about 1 ng/mg and ~~present in less than or equal to about~~ 50 ng/mg, the percentage of aggregates in the composition is between about 0.001% and 0.3%, and the percentage of monomer in the composition between about 99.5% and 99.999%, wherein the anti-c-met antibody comprises:

a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKD RFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19); and

(b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20)~~a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6),~~ wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0039] ~~In one aspect, there is provided~~Disclosed is a composition comprising an anti-c-met antibody, wherein HCP is present in less than or equal to about 50 ng/mg, the DNA levels in the composition comprising an anti-c-met antibody are less than or equal to about 0.3 pg/mg, the LpA in the composition comprising an anti-c-met antibody is less than or equal to about 2 ng/mg, the Limulus Amebocyte Lysate (LAL) in the composition comprising an anti-c-met antibody is less than or equal to about 0.01 EU/mg, the percentage of aggregates in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of monomer in the composition comprising an anti-c-met antibody is greater than or equal to about 99.5%, the percentage of fragments in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of acidic variants in the composition comprising an anti-c-met antibody is less than or equal to about 20%, the percentage of main peak in the composition comprising an anti-c-met antibody is greater than or equal to about 75%, and the percentage of basic variants in the composition comprising an anti-c-met antibody is less than or equal to about 2.0%, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0040] ~~In one aspect, there is provided~~Disclosed is a composition comprising an anti-c-met antibody, wherein HCP is present in less than or equal to about 15 ng/mg, the DNA levels in the composition comprising an anti-c-met antibody are less than or equal to about 0.3 pg/mg, the LpA in the composition comprising an anti-c-

met antibody is less than or equal to about 2 ng/mg, the Limulus Amebocyte Lysate (LAL) in the composition comprising an anti-c-met antibody is less than or equal to about 0.01 EU/mg, the percentage of aggregates in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of monomer in the composition comprising an anti-c-met antibody is greater than or equal to about 99.5%, the percentage of fragments in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of acidic variants in the composition comprising an anti-c-met antibody is less than or equal to about 20%, the percentage of main peak in the composition comprising an anti-c-met antibody is greater than or equal to about 75%, and the percentage of basic variants in the composition comprising an anti-c-met antibody is less than or equal to about 2.0%, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0041] In one aspect, there is provided a method of purifying an anti-c-met antibody comprising keeping a composition comprising the anti-c-met antibody at a temperature of between about ~~greater than~~ 28°C-35°C and a pH between about pH 6 and about pH 8 for ~~more than 6~~ between about 6-48 hours, wherein the anti-c-met antibody comprises: (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19); and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20) ~~a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6)~~, wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex. In some embodiments, the method further comprises centrifuging the composition comprising the anti-c-met antibody. In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on MabSelect SuRe resin and eluting the anti-c-met antibody.

[0042] ~~In one aspect, there is provided~~Disclosed is a method of purifying an anti-c-met antibody comprising loading a composition comprising an anti-c-met antibody on MabSelect SuRe resin and eluting the anti-c-met antibody, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a

Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

[0043] In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through. In some embodiments, the weak anion exchange resin is run in flow-through mode.

[0044] ~~In one aspect, there is provided~~Disclosed is a method of purifying an anti-c-met antibody comprising loading a composition comprising an anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex. In some embodiments, the weak anion exchange resin is run in flow-through mode.

[0044a] In one aspect, there is provided a method of purifying an anti-c-met antibody comprising keeping a composition comprising the anti-c-met antibody at a temperature of between about 28°C-35°C and a pH between about pH 6 and about pH 8 for between about 6-48 hours, wherein the anti-c-met antibody comprises: (a) a heavy chain variable domain comprising the sequence: EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKD RFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19); and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex, wherein the method further comprises centrifuging the composition comprising the anti-c-met antibody, wherein the method further comprises loading the composition comprising the anti-c-met antibody on Protein A resin and eluting the anti-c-met antibody, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through, followed by loading the composition comprising the anti-c-met antibody on a strong cation exchange resin and eluting the anti-c-met antibody, followed by loading the composition comprising the anti-c-met antibody on a strong anion exchange resin and eluting the anti-c-met antibody.

[0045] In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on a strong cation exchange resin and eluting the anti-c-met antibody. In some embodiments, the method further comprises loading the composition comprising the anti-c-met antibody on a strong anion exchange resin and eluting the anti-c-met antibody. In some embodiments, the method further comprises ultrafiltering and/or diafiltering the composition comprising the anti-c-met antibody.

[0046] In one aspect, there is provided a composition comprising an anti-c-met antibody purified or obtainable by any of the methods as defined above~~, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex~~.

[0046a] In one aspect, there is provided a pharmaceutical formulation comprising the composition as defined above.

[0046b] In one aspect, there is provided use of the pharmaceutical formulation as defined above in the manufacture of a medicament for inhibiting c-met activated cell proliferation, wherein the medicament is to be contacted with a cell or tissue.

CLAIMS

1. A composition comprising an anti-c-met antibody, wherein host cell protein (HCP) is present in less than or equal to about 50 ng/mg, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

2. A composition comprising an anti-c-met antibody, wherein HCP is present in less than or equal to about 50 ng/mg, the DNA levels in the composition comprising an anti-c-met antibody are less than or equal to about 0.3 pg/mg, the LpA in the composition comprising an anti-c-met antibody is less than or equal to about 2 ng/mg, the Limulus Amebocyte Lysate (LAL) in the composition comprising an anti-c-met antibody is less than or equal to about 0.01 EU/mg, the percentage of aggregates in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of monomer in the composition comprising an anti-c-met antibody is greater than or equal to about 99.5%, the percentage of fragments in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of acidic variants in the composition comprising an anti-c-met antibody is less than or equal to about 20%, the percentage of main peak in the composition comprising an anti-c-met antibody is greater than or equal to about 75%, and the percentage of basic variants in the composition comprising an anti-c-met antibody is less than or equal to about 2.0%, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

3. A composition comprising an anti-c-met antibody, wherein HCP is present in less than or equal to about 15 ng/mg, the DNA levels in the composition comprising an anti-c-met antibody are less than or equal to about 0.3 pg/mg, the LpA in the composition comprising an anti-c-met antibody is less than or equal to about 2 ng/mg, the Limulus Amebocyte Lysate (LAL) in the composition comprising an anti-c-met antibody is less than or equal to about 0.01 EU/mg, the percentage of aggregates in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the percentage of monomer in the composition comprising an anti-c-met antibody is greater than or equal to about 99.5%, the percentage of fragments in the composition comprising an anti-c-met antibody is less than or equal to about 0.3%, the

percentage of acidic variants in the composition comprising an anti-c-met antibody is less than or equal to about 20%, the percentage of main peak in the composition comprising an anti-c-met antibody is greater than or equal to about 75%, and the percentage of basic variants in the composition comprising an anti-c-met antibody is less than or equal to about 2.0%, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

4. A method of purifying an anti-c-met antibody comprising keeping a composition comprising the anti-c-met antibody at a temperature of greater than 28°C and a pH between about pH 6 and about pH 8 for more than 6 hours, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

5. The method of claim 4, wherein the method further comprises centrifuging the composition comprising the anti-c-met antibody.

6. The method of any one of claims 4-5, wherein the method further comprises loading the composition comprising the anti-c-met antibody on MabSelect SuRe resin and eluting the anti-c-met antibody.

7. A method of purifying an anti-c-met antibody comprising loading a composition comprising an anti-c-met antibody on MabSelect SuRe resin and eluting the anti-c-met antibody, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

8. The method of any one of claims 4-7, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a weak anion exchange resin and recovering the anti-

c-met antibody in the flow-through.

9. The method of claim 8, wherein the weak anion exchange resin is run in flow-through mode.

10. A method of purifying an anti-c-met antibody comprising loading a composition comprising an anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

11. The method of claim 10, wherein the weak anion exchange resin is run in flow-through mode.

12. The method of any one of claims 4-11, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a strong cation exchange resin and eluting the anti-c-met antibody.

13. The method of any one of claims 4-12, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a strong anion exchange resin and eluting the anti-c-met antibody.

14. The method of any one of claims 4-13, wherein the method further comprises ultrafiltering and/or diafiltering the composition comprising the anti-c-met antibody.

15. A composition comprising an anti-c-met antibody purified or obtainable by any of the methods of claims 4-14, wherein the anti-c-met antibody comprises a HVR-L1 comprising sequence KSSQSLLYTSSQKNYLA (SEQ ID NO:1), a HVR-L2 comprising sequence WASTRES (SEQ ID NO:2), a HVR-L3 comprising sequence QQYYAYPWT (SEQ ID NO:3), a HVR-H1 comprising sequence GYTFTSYWLH (SEQ ID NO:4), a HVR-H2 comprising sequence GMIDPSNSDTRFNPNFKD (SEQ ID NO:5), and a HVR-H3 comprising sequence ATYRSYVTPLDY (SEQ ID NO:6), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

16. The composition of claim 15, wherein host cell protein (HCP) is present in less than or equal to about 50 ng/mg.

17. The composition of claims 1-2 or 16, wherein the HCP is present in between about 1 ng/mg and 15 ng/mg.

18. The composition of any one of claims 1-3 or 16-17, wherein the HCP is *E. coli* protein (ECP).

19. The composition or method of any one of claims 1-18, wherein the anti-c-met antibody comprises (a) a heavy chain variable domain comprising the sequence:

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPN FKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19) and (b) a light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20).

20. The composition or method of claim 19, wherein the Fc region increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm.

21. The composition or method of any one of claims 1-20, wherein the first Fc polypeptide comprises the Fc sequence depicted in Figure 1 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in Figure 2 (SEQ ID NO: 18).

22. The composition or method of any one of claims 1-21, wherein the anti-c-met antibody is onartuzumab.

23. The composition or method of any one of claims 1-22, wherein the anti-c-met antibody binds the same epitope as onartuzumab.

24. The composition or method of any one of claims 1-23, wherein the anti-c-met antibody has a pI of between about 8.0 and about 8.5.

25. A pharmaceutical formulation comprising the composition of any one of claims 1-3 or 15-24.

26. Use of the pharmaceutical formulation of claim 25 in the manufacture of a medicament for inhibiting c-met activated cell proliferation, wherein the medicament is to be contacted with a cell or tissue.

27. Use of the pharmaceutical formulation of claim 25 in the manufacture of a medicament for modulating a disease associated with dysregulation of the HGF/c-met signaling axis in a subject.

28. Use of the pharmaceutical formulation of claim 25 in the manufacture of a medicament for treating a subject having a proliferative disorder.

29. The use of claim 28, wherein the proliferative disorder is cancer.

30. The use of claim 29, wherein the cancer is lung cancer, glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, and/or breast cancer.

31. The use of any one of claims 26-30, wherein the medicament further comprises a second therapeutic agent.

32. An article of manufacture comprising a container with the pharmaceutical formulation of claim 25 contained therein.

33. A method of making the article of manufacture of claim 32.

34. An *in vitro* method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation of claim 25.

35. The method of claim 34, further comprising administering a second therapeutic agent.

CLAIMS

1. A composition comprising an anti-c-met antibody, wherein host cell protein (HCP) is between about 1 ng/mg and 50 ng/mg, the percentage of aggregates in the composition is between about 0.001% and 0.3%, and the percentage of monomer in the composition between about 99.5% and 99.999%, wherein the anti-c-met antibody comprises:

a) a heavy chain variable domain comprising the sequence:

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRF NPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19); and

(b) a light chain variable domain comprising the sequence:

DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRES GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

2. The composition of claim 1, wherein the DNA levels in the composition are between about 0.001 pg/mg and 0.3 pg/mg, the leached protein A (LpA) in the composition is between about 0.001 ng/mg and 2 ng/mg, the Limulus Amebocyte Lysate (LAL) in the composition is between about 0.0001 EU/mg and 0.01 EU/mg, the percentage of fragments in the composition is between about 0.001% and 0.3%, the percentage of acidic variants in the composition is between about 1% and 20%, the percentage of main peak in the composition is between about 75% and 95%, and the percentage of basic variants in the composition is between about 0.001% and 2.0%.

3. The composition of claim 1 or 2, wherein HCP is present between about 1 ng/mg and 15 ng/mg.

4. A method of purifying an anti-c-met antibody comprising keeping a composition comprising the anti-c-met antibody at a temperature of between about 28°C-35°C and a pH between about pH 6 and about pH 8 for between about 6-48 hours, wherein the anti-c-met antibody comprises:

(a) a heavy chain variable domain comprising the sequence:

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRF NPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS (SEQ ID NO:19); and

(b) a light chain variable domain comprising the sequence:

DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRES GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID NO:20), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

5. The method of claim 4, wherein the composition further comprises polyethyleneimine at a concentration of about any of 0.1-0.4% (v/v).

6. The method of claim 4 or 5, wherein the method further comprises centrifuging the composition comprising the anti-c-met antibody.

7. The method of any one of claims 4-6, wherein the method further comprises loading the composition comprising the anti-c-met antibody on protein A resin and eluting the anti-c-met antibody.

8. The method of any one of claims 4-7, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through.

9. The method of claim 8, wherein the weak anion exchange resin is run in flow-through mode.

10. The method of any one of claims 4-9, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a strong cation exchange resin and eluting the anti-c-met antibody.

11. The method of any one of claims 4-10, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a strong anion exchange resin and eluting the anti-c-met antibody.

12. A method of purifying an anti-c-met antibody comprising keeping a composition comprising the anti-c-met antibody at a temperature of between about 28°C-35°C and a pH between about pH 6 and about pH 8 for between about 6-48 hours, wherein the anti-c-met antibody comprises:

(a) a heavy chain variable domain comprising the sequence:
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRF
NPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS
(SEQ ID NO:19); and

(b) a light chain variable domain comprising the sequence:
DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRES
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID
NO:20), wherein the anti-c-met antibody comprises a single antigen binding arm and comprises a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex, wherein the method further comprises centrifuging the composition comprising the anti-c-met antibody, wherein the method further comprises loading the composition comprising the anti-c-met antibody on Protein A resin and eluting the anti-c-met antibody, wherein the method further comprises loading the composition comprising the anti-c-met antibody on a weak anion exchange resin and recovering the anti-c-met antibody in the flow-through, followed by loading the composition comprising the anti-c-met antibody on a strong cation exchange resin and eluting the anti-c-met antibody, followed by loading the composition comprising the anti-c-met antibody on a strong anion exchange resin and eluting the anti-c-met antibody.

13. The method of any one of claims 4-12, wherein the method further comprises ultrafiltering and/or diafiltering the composition comprising the anti-c-met antibody.

14. A composition comprising an anti-c-met antibody purified or obtainable by any of the methods of claims 4-13.

15. The composition of claim 14, wherein host cell protein (HCP) is between about 1 ng/mg and 50 ng/mg.

16. The composition of claims 1-2 or 15, wherein the HCP is present in between about 1 ng/mg and 15 ng/mg.

17. The composition of any one of claims 1-3 or 15-16, wherein the HCP is *E. coli* protein (ECP).

18. The composition or method of any one of claims 1-17, wherein the first Fc polypeptide comprises the Fc sequence depicted in Figure 1 (SEQ ID NO: 17) and the second Fc polypeptide comprises the Fc sequence depicted in Figure 2 (SEQ ID NO: 18).

19. The composition or method of any one of claims 1-18, wherein the anti-c-met antibody is onartuzumab.

20. The composition or method of any one of claims 1-19, wherein the anti-c-met antibody has a pI of between about 8.0 and about 8.5.

21. A pharmaceutical formulation comprising the composition of any one of claims 1-3 or 14-20.

22. Use of the pharmaceutical formulation of claim 21 in the manufacture of a medicament for inhibiting c-met activated cell proliferation, wherein the medicament is to be contacted with a cell or tissue.

23. Use of the pharmaceutical formulation of claim 21 in the manufacture of a medicament for modulating a disease associated with dysregulation of the HGF/c-met signaling axis in a subject.

24. Use of the pharmaceutical formulation of claim 21 in the manufacture of a medicament for treating a subject having a proliferative disorder.

25. The use of claim 24, wherein the proliferative disorder is cancer.

26. The use of claim 25, wherein the cancer is lung cancer, glioblastoma, pancreatic cancer, sarcoma, renal cell carcinoma, hepatocellular carcinoma, gastric cancer, colorectal cancer, and/or breast cancer.

27. The use of any one of claims 22-26, wherein the medicament further comprises a second therapeutic agent.

28. An article of manufacture comprising a container with the pharmaceutical formulation of claim 21 contained therein.

29. A method of making the article of manufacture of claim 28.

30. An *in vitro* method of inhibiting c-met activated cell proliferation, said method comprising contacting a cell or tissue with an effective amount of the pharmaceutical formulation of claim 21.

31. The method of claim 30, further comprising administering a second therapeutic agent.